Cargando…
Rheumatic Musculoskeletal Diseases and COVID-19 A Review of the First 6 Months of the Pandemic
In December 2019, a cluster of severe pneumonia was observed in China, with the subsequent discovery of a new beta-coronavirus (SARS-CoV-2) as the causative agent. The elicited disease COVID-19 is characterized by fever, dry cough, myalgia, or fatigue and has a favorable outcome in the majority of c...
Autores principales: | Stradner, Martin H., Dejaco, Christian, Zwerina, Jochen, Fritsch-Stork, Ruth D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586311/ https://www.ncbi.nlm.nih.gov/pubmed/33154972 http://dx.doi.org/10.3389/fmed.2020.562142 |
Ejemplares similares
-
Current Practice of Imaging-Guided Interventional Procedures in Rheumatic and Musculoskeletal Diseases: Results of a Multinational Multidisciplinary Survey
por: Carubbi, Francesco, et al.
Publicado: (2021) -
Editorial: Psychological impact and quality of life in rheumatic and musculoskeletal diseases
por: Talarico, Rosaria, et al.
Publicado: (2023) -
Editorial: Advance in B-cell therapies for the treatment of rheumatic and musculoskeletal diseases
por: Md Yusof, Md Yuzaiful, et al.
Publicado: (2022) -
Outcomes of COVID-19 in people with rheumatic and musculoskeletal disease in Ireland over the first 2 years of the pandemic
por: Conway, Richard, et al.
Publicado: (2023) -
Cannabidiol (CBD) in Rheumatic Diseases (Musculoskeletal Pain)
por: Boehnke, Kevin F., et al.
Publicado: (2022)